



**Blood and Transplant**

**ANNUAL REPORT ON MECHANICAL  
CIRCULATORY SUPPORT RELATED TO  
HEART TRANSPLANTATION**

**REPORT FOR 2017/2018  
(1 APRIL 2008 – 31 MARCH 2018)**

**PUBLISHED FEBRUARY 2019**

**PRODUCED IN COLLABORATION WITH NHS ENGLAND**



# CONTENTS



## Contents

<b>1</b>	<b>Executive summary</b>	<b>4</b>
<b>2</b>	<b>Introduction</b>	<b>6</b>
	<b>ADULT LONG-TERM DEVICES USED FOR BRIDGING</b>	<b>13</b>
3	Activity	13
4	Patient outcomes	17
4.1	Duration on support	18
4.2	Rate of transplant listing	20
4.3	Competing outcomes	21
4.4	Survival on support	22
4.5	Patient survival from implant	24
4.6	TAH outcomes	29
	<b>ADULT SHORT-TERM DEVICES USED FOR BRIDGING</b>	<b>30</b>
5	Activity	30
6	Patient outcomes	34
6.1	Duration on support	35
6.2	Rate of transplant listing	37
6.3	Competing outcomes	38
6.4	Survival on support	39
6.5	Patient survival from implant	41
6.6	Bridge to long-term device	46
	<b>ADULT SHORT-TERM DEVICES USED POST-HEART TRANSPLANT</b>	<b>47</b>
7	Activity	47
8	Patient outcomes	51
8.1	Duration on support	52
8.2	Patient survival from implant	53
	<b>PAEDIATRIC DEVICES USED FOR BRIDGING</b>	<b>57</b>
9	Activity	57
10	Patient outcomes	61
10.1	Duration on support	62
10.2	Rate of transplant listing	64
10.3	Competing outcomes	65
10.4	Patient survival from implant	66
	<b>APPENDIX</b>	<b>69</b>
A1:	Data	70
A2:	Methods	74
A3:	Glossary of terms	75

# **EXECUTIVE SUMMARY**



## 1 Executive Summary

This report summarises key information about mechanical circulatory support (MCS) used in patients in the UK as a bridge to heart transplantation or for post-transplant support. MCS in this context includes [long-term](#) ventricular assist devices ([VADs](#)), [short-term](#) VADs, total artificial hearts ([TAH](#)) and veno-arterial extracorporeal membrane oxygenation ([ECMO](#)). The period reported covers 10 years of MCS activity, from 1 April 2008 to 31 March 2018, however paediatric data are only available since 1 April 2013. Data were obtained from the UK [VAD Database](#) held by NHS Blood and Transplant as at 11 January 2019. Results are generally presented separately for adult and paediatric patients, for long-term and short-term devices and for bridging or post-transplant strategies.

### Key findings

Long-term bridging devices in adults:

- During 2017/2018 there were 108 long-term device implantations, including 103 long-term VADs and 5 TAHs. This represents a 3% decline from the previous year.
- Almost half (47%) of long-term VAD implantations last year were into [INTERMACS patient profile 2](#) (progressive decline) or 3 (stable but inotrope dependent) patients.
- The median duration on long-term VAD support was 675 days (1.8 years).
- At 1-year post-implant, 63% of patients were alive on support, 28% had died on support, 7% had been transplanted and 2% were explanted without transplant.
- The 1-year survival rate from the point of first long-term VAD implant (not censored for transplant or explant) was 70.6%.

Short-term bridging devices in adults:

- During 2017/2018 there were 115 short-term device implantations into 104 patients, including 66 VADs and 49 ECMOs; a 58% increase from the previous year.
- The majority (70%) of implantations last year were into [INTERMACS patient profile 1](#) patients (critical cardiogenic shock).
- The [median](#) duration on short-term support was 13 days.
- At 30 days post-implant, 25% of patients were alive on support, 25% had died on support, 15% had been transplanted, 17% transferred to a long-term device and 19% were explanted without transplant.
- The 1-year survival rate from the point of first short-term VAD implant (not censored for transplant or explant) was 44.8%.

Short-term devices used for PGD in adults:

- During 2017/2018 there were 42 short-term device implantations for PGD into 32 patients, including 36 ECMOs and 6 VADs; a 14% increase from the previous year.
- On average, patients spent 5 days on support and 47.1% survived to 1-year post-implant.

Bridging devices used in paediatrics:

- During 2017/2018 there were 28 device implantations into 22 paediatric patients
- On average, patients spent 59 days on support
- 46% of patients received a transplant within 90 days of implantation and 79.7% survived to 1-year post-implant.

Use of the contents of this report should be acknowledged as follows:

*Annual Report on Mechanical Circulatory Support Related to Heart Transplantation 2017/2018, NHS Blood and Transplant*

# **INTRODUCTION**



## 2 Introduction

In the United Kingdom, mechanical circulatory support (MCS) therapy is commissioned as a bridge to heart transplantation or for post-transplant support due to primary graft dysfunction ([PGD](#)) or [rejection](#). MCS in this context includes [long-term](#) ventricular assist devices ([VADs](#)), [short-term](#) VADs, total artificial hearts ([TAH](#)) and veno-arterial extracorporeal membrane oxygenation ([ECMO](#)). The seven centres that provide this service are those that also provide heart transplantation: Birmingham Queen Elizabeth Hospital, Harefield Hospital, Manchester Wythenshawe Hospital, Newcastle Freeman Hospital, Papworth Hospital, Great Ormond Street Hospital and Glasgow Golden Jubilee Hospital. Great Ormond Street Hospital provide a paediatric (age less than 16 years) service only, Newcastle provide both adult and paediatric services, and the remaining centres provide adult services only.

All centres are required to submit data to the national database hosted by NHS Blood and Transplant, known as the [VAD Database](#). The database collects extensive data prior to and at time of device implant, explant, transplant and death along with follow-up at various time points post-implant and post-explant. These data are audited and reported annually in this report in order to provide centres, commissioners and patients with relevant and transparent information about the UK MCS service. The report also incorporates data from the [UK Transplant Registry](#) on listing for heart transplantation and survival after transplant for patients receiving MCS.

The cohort covered in this report is from 1 April 2008 to 31 March 2018, however paediatric data are only presented for the period 1 April 2013 to 31 March 2018 since before 2013 there was no national data capture for paediatric MCS therapy. Data were obtained from the database as at 11 January 2019 by which date it was expected that most devices used during the audit period had been reported to the database.

Prior to the introduction of the General Data Protection Regulation (GDPR) in May 2018, consent had to be gained from patients to record their data on the [VAD Database](#). During this time 15 patients refused consent and so these patients are excluded from this report. From May 2018, patient data are recorded lawfully without explicit consent under Section 6(1)e of the GDPR. Use of Section 6(1)e requires a specific exemption and the patient data is being collected and processed under Section 9(2)h “management of healthcare”.

The report is split into four main parts:

- [Adult long-term devices used for bridging](#) (long-term VADs and TAH)
- [Adult short-term devices used for bridging](#) (short-term VADs and ECMO)
- [Adult short-term devices used post-heart transplant](#) (short-term VADs and ECMO)
- [Paediatric devices used for bridging](#) (short- and long- term VADs and ECMO)

Each part includes an activity section where data are analysed on a per-implant basis and a patient outcome section where data are analysed on a per-patient basis. Activity is analysed over the decade whilst outcomes are typically analysed for patients receiving MCS in a recent 4 year period (1 April 2013 – 31 March 2017 for this report). See [Appendix A1](#) for a breakdown of the number of observations analysed in each section and notes on classifications and limitations.


Methods used to produce the report are described in [Appendix A2](#).

Patient survival is analysed in two ways; from the point of first device implant to death, irrespective of subsequent intervention, and survival on support which is time from short-term or long-term VAD implant to death on support where explant or transplant events are censored. The reader should note that in both cases the results are not adjusted for potential differences in risk between patients treated at different centres. Such differences in “case-mix” may explain any variation in the centre-specific survival rates, thus no conclusions can be made about differences in the standard of care between centres. Further work is needed to identify the relevant risk-factors to adjust for to calculate risk-adjusted survival rates.

## 2.1 Overview

**Figure 2.1** shows the number of implants for bridging in the last ten years, split by device type. Up to 2015/2016, long-term implant activity increased steadily to a peak of 141 devices but has since decreased to 125 in 2017/2018. Short-term device usage increased up to 104 in 2014/2015 but has since decreased before reaching a peak of 126 in 2017/2018. In total there were 1,514 bridging implants across the decade into 1,237 patients; 999 (81%) patients had a single device implant, 205 (17%) had two implants, 27 (2%) had three and 6 (0.5%) had four (see **Table A1.3** in [Appendix A1](#) for details of device histories).


**Figure 2.1 Total number of bridging device implants in the UK (adult and paediatric), by device type and financial year, 1 April 2008 to 31 March 2018**



**Figure 2.2** shows the number of implants post-heart transplant in the last ten years, split by primary graft dysfunction and rejection strategies. The number of implants for PGD has increased over the period, reaching 42 in 2017/2018. Devices used for rejection remain relatively rare, with three performed in 2017/2018. In total there were 258 post-transplant implants across the decade into 219 patients; 186 (85%) patients had a single device implant, 28 (13%) had two implants, 4 (2%) had three and 1 (0.5%) had four (see **Table A1.4** in [Appendix A1](#) for details of device histories).



**Figure 2.2 Total number of post-transplant device implants in the UK (adult and paediatric), by strategy and financial year, 1 April 2008 to 31 March 2018**



**Table 2.1** and **2.2** summarise the number of patients and implants that have been reported to the VAD Database by centres for the period 1 April 2008 to 31 March 2018 and separately for the most recent year, 1 April 2017 to 31 March 2018. **Table 2.1** reflects the bridge to transplant data while **Table 2.2** reflects the post-transplant data.

**Table 2.1 Number of patients receiving bridging devices and number of implants, by age group and centre, during the decade and the most recent year**

Age group	Centre	1 April 2008 - 31 March 2018						1 April 2017 - 31 March 2018					
		No. implants	LT VAD	Type of device TAH ST VAD ECMO			No. patients	No. implants	LT VAD	Type of device TAH ST VAD ECMO			No. patients
Adult	Birmingham	<b>220</b>	109	0	71	40	177	<b>50</b>	28	0	16	6	41
	Glasgow	<b>90</b>	20	0	45	25	75	<b>18</b>	1	0	9	8	16
	Harefield	<b>406</b>	283	18	58	47	303	<b>64</b>	32	5	18	9	47
	Manchester	<b>201</b>	94	0	68	39	163	<b>39</b>	15	0	13	11	34
	Newcastle	<b>299</b>	242	1	3	53	262	<b>32</b>	19	0	0	13	30
	Papworth	<b>172</b>	94	2	47	29	150	<b>20</b>	8	0	10	2	19
	<b>Total</b>	<b>1388</b>	<b>842</b>	<b>21</b>	<b>292</b>	<b>233</b>	<b>1130</b>	<b>223</b>	<b>103</b>	<b>5</b>	<b>66</b>	<b>49</b>	<b>187</b>
Paediatric <sup>1</sup>													
	<b>Total</b>	<b>126</b>	<b>86</b>	<b>0</b>	<b>33</b>	<b>7</b>	<b>107</b>	<b>28</b>	<b>17</b>	<b>0</b>	<b>11</b>	<b>0</b>	<b>22</b>
<b>TOTAL</b>	<b>1514</b>	<b>928</b>	<b>21</b>	<b>325</b>	<b>240</b>	<b>1237</b>	<b>251</b>	<b>120</b>	<b>5</b>	<b>77</b>	<b>49</b>	<b>209</b>	

LT VAD=Long-Term Ventricular Assist Device, TAH=Total Artificial Heart, ST VAD=Short-Term Ventricular Assist Device, ECMO=Extra Corporeal Membrane Oxygenation

<sup>1</sup> For paediatric patients, Berlin Heart Excor and Heartware are classed as long-term devices and Centrimag is classed as short-term


**Table 2.2 Number of patients receiving post-transplant devices and number of implants, by age group and centre, during the decade and the most recent year**

Age group	Centre	1 April 2008 - 31 March 2018									1 April 2017 - 31 March 2018				
		No. implants	Primary graft dysfunction				Rejection			No. patients	No. implants	Primary graft dysfunction		Rejection	No. patients
			LT VAD	TAH	ST VAD	ECMO	LT VAD	ST VAD	ECMO			ST VAD	ECMO	ECMO	
Adult	Birmingham	45	0	0	10	29	0	4	2	36	9	2	7	0	6
	Glasgow	41	0	0	12	26	0	1	2	31	4	2	2	0	3
	Harefield	43	0	1	16	26	0	0	0	40	3	0	3	0	3
	Manchester	57	0	0	8	49	0	0	0	50	7	0	7	0	7
	Newcastle	41	3	0	1	33	0	0	4	35	13	0	10	3	9
	Papworth	29	0	0	6	23	0	0	0	25	9	2	7	0	6
	<b>Total</b>	<b>256</b>	<b>3</b>	<b>1</b>	<b>53</b>	<b>186</b>	<b>0</b>	<b>5</b>	<b>8</b>	<b>217</b>	<b>45</b>	<b>6</b>	<b>36</b>	<b>3</b>	<b>34</b>
Paediatric	1 April 2013 - 31 March 2018														
	Centre	No. implants	Primary graft dysfunction				Rejection			No. patients	No. implants	Primary graft dysfunction		Rejection	No. patients
			LT VAD	TAH	ST VAD	ECMO	LT VAD	ST VAD	ECMO			ST VAD	ECMO	ECMO	
Great Ormond Street	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
Newcastle	2	0	0	0	0	2	0	0	2	0	0	0	0	0	
<b>Total</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	
<b>TOTAL</b>	<b>258</b>	<b>3</b>	<b>1</b>	<b>53</b>	<b>186</b>	<b>2</b>	<b>5</b>	<b>8</b>	<b>219</b>	<b>45</b>	<b>6</b>	<b>36</b>	<b>3</b>	<b>34</b>	

LT VAD=Long-Term Ventricular Assist Device, TAH=Total Artificial Heart, ST VAD=Short-Term Ventricular Assist Device, ECMO=Extra Corporeal Membrane Oxygenation

**Figure 2.3** shows the number of patients receiving MCS as a bridge to heart transplant per million population (pmp) between 1 April 2017 and 31 March 2018, by country/Strategic Health Authority (SHA) of patient residence. No adjustments have been made for potential demographic differences in populations. Overall, the number of patients receiving MCS was 3.0 pmp of the UK. Since there will inevitably be some random variation in rates between areas, the systematic component of variation (SCV) was used to identify if the variation is more (or less) than a random effect for the different SHAs in England only. The larger the SCV the greater the evidence of a high level of systematic variation between areas. The implant rate yielded a SCV at 0.2 which indicates some evidence of geographical variation beyond that which would be expected at random.

**Figure 2.3** Number of patients receiving MCS as a bridge to heart transplantation per million population (pmp) in the UK, 1 April 2017 – 31 March 2018, by country/Strategic Health Authority of patient residence



Country/ Strategic Health Authority	Number of patients receiving bridging devices (pmp)	
North East	16	(6.1)
North West	31	(4.3)
Yorkshire and The Humber	16	(2.9)
<b>North of England</b>	<b>63</b>	<b>(4.1)</b>
East Midlands	7	(1.5)
West Midlands	32	(5.5)
East of England	11	(1.8)
<b>Midlands and East</b>	<b>50</b>	<b>(3.0)</b>
<b>London</b>	<b>23</b>	<b>(2.6)</b>
South East Coast	10	(2.1)
South Central	14	(3.2)
South West	14	(2.5)
<b>South of England</b>	<b>38</b>	<b>(2.6)</b>
<b>England</b>	<b>174</b>	<b>(3.1)</b>
Isle of Man	2	(25.0)
Channel Islands	0	-
<b>Wales</b>	<b>6</b>	<b>(1.9)</b>
<b>Scotland</b>	<b>17</b>	<b>(3.1)</b>
<b>Northern Ireland</b>	<b>6</b>	<b>(3.2)</b>
<b>TOTAL</b>	<b>208<sup>1</sup></b>	<b>(3.2)</b>

<sup>1</sup> Implants include 3 recipients whose postcode was unknown and excludes 1 recipients who reside in the Republic of Ireland

# **ADULT LONG-TERM DEVICES USED FOR BRIDGING**

**Activity**




### 3 Long-term bridging devices in adults


This section considers all patients who received a [long-term device](#) as a bridge to heart transplantation. All figures and tables in this section present information on a per implant basis as opposed to per patient, so if a single patient had more than one long-term device implantation in the time period, each is included. If a patient had a previous [short-term device](#), their long-term device is included.

**Figure 3.1** shows the total number of long-term bridging device implants in the last ten years nationally by device type (long-term VAD or [TAH](#)). During 2017/2018 there were 108 implantations; 3 fewer than 2016/2017 and 2.6 times higher than in 2008/2009. In total there were 21 TAH implantations. **Figure 3.2** shows the trend per centre, with Birmingham and Manchester having the most marked increases in implantations over the decade. Last year's activity is shown by centre and device type in **Figure 3.3**. The highest number of implantations was performed by Harefield and Birmingham, followed by Newcastle.


**Figure 3.1** Number of adult long-term bridging device implants in the UK, by financial year and device type, 1 April 2008 to 31 March 2018



**Figure 3.2** Number of adult long-term bridging device implants in the UK, by financial year, centre and device type, 1 April 2008 to 31 March 2018




**Figure 3.3** Number of adult long-term bridging device implants in the UK, by centre and device type, 1 April 2017 to 31 March 2018



**Figure 3.4** shows the [INTERMACS patient profile](#) at time of long-term VAD implantation for patients implanted during 2017/2018. Level 2 (progressive decline) was the most common, followed by level 1 (critical cardiogenic shock) and level 3 (stable but inotrope dependent).

**Figure 3.4** INTERMACS patient profile of adult patients receiving long-term bridging device implants during 1 April 2017 – 31 March 2018





# **ADULT LONG-TERM DEVICES USED FOR BRIDGING**

**Patient Outcomes**



## 4 Outcomes for adult patients with long-term bridging devices


This section only considers patients whose first long-term device was a [continuous-flow](#) long-term VAD. Patients who received prior short-term support are excluded from this section, apart from [Section 4.4](#) which considers survival on long-term support. Patients with no follow-up information available are also excluded from this section as we cannot assume information about their time on support. Patients who received a Total Artificial Heart are considered separately in [Section 4.6](#). Patients are analysed on a per-patient basis.

### 4.1 Duration on support

**Table 4.1** shows the [median](#) duration on long-term VAD support for patients implanted in a recent four year period, both nationally and by centre. The [medians](#) and [confidence intervals](#) are estimated using the [Kaplan-Meier method](#) since not all patients have come to the end of their support and this method allows these (censored) patients to be included in the analysis. Transplant, explant or death signify end of support. If a patient was subsequently given a short-term device, only time on the long-term device is counted. Nationally, the [median](#) time on long-term support was 675 days and ranged from 467 days at Newcastle to 1,477 days at Birmingham (log-rank  $p < 0.0001$ ).

<b>Table 4.1 Median duration on long-term VAD support for adult patients implanted between 1 April 2013 and 31 March 2017, by centre</b>			
Centre	Number of patients	Time on support (days)	
		<a href="#">Median</a>	(95% <a href="#">confidence interval</a> )
Birmingham	57	1477	1017 - 1937
Glasgow	3	527	485 - 569
Harefield	93	645	277 - 1013
Manchester	46	1250	726 - 1774
Newcastle	91	467	351 - 583
Papworth	35	588	297 - 879
<b>Overall</b>	<b>325</b>	<b>675</b>	<b>492 - 858</b>


**Figure 4.1 Median duration on long-term VAD support for adult patients implanted between 1 April 2013 and 31 March 2017**



## 4.2 Rate of transplant listing

**Figure 4.2** and **Table 4.2** show the rate of transplant listing for patients first implanted between 1 April 2013 and 31 March 2017, by centre. This includes listing on the super-urgent, urgent or non-urgent heart transplant lists (whichever occurred first). Overall, 41% of patients were listed prior to implant, but this proportion ranged from 20% at Harefield to 71% at Papworth (chi-square  $p < 0.0001$ ). The proportion still on a VAD at one year and not listed was 28% overall and ranged from 4% at Newcastle to 57% at Manchester (chi-square  $p < 0.0001$ ).

**Figure 4.2 Heart transplant listing status with respect to long-term VAD implantation for adult patients receiving a first device 1 April 2013 – 31 March 2017, by centre and overall**




Centre	Number of patients N	Listed before VAD implant N (%)	Listed within 1 year N (%)	Not listed within 1 year N (%)	Died/explanted within 1 year without listing N (%)
Birmingham	57	16 (28)	11 (19)	24 (42)	6 (11)
Glasgow	3	2 (67)	1 (33)	0 (0)	0 (0)
Harefield	93	19 (20)	15 (16)	36 (39)	23 (25)
Manchester	46	10 (22)	4 (9)	26 (57)	6 (13)
Newcastle	91	61 (67)	18 (20)	4 (4)	8 (9)
Papworth	35	25 (71)	6 (17)	2 (6)	2 (6)
<b>Overall</b>	<b>325</b>	<b>133 (41)</b>	<b>55 (17)</b>	<b>92 (28)</b>	<b>45 (14)</b>

### 4.3 Competing outcomes

Whilst on VAD support, patients are susceptible to different outcomes. Death on support, transplant, and explant without transplant (with or without recovery) are all possible outcomes. **Figure 4.3** shows the [cumulative incidence](#) of each of these outcomes occurring from time of implantation, for the cohort of patients receiving a first long-term device between 1 April 2013 and 31 March 2017. This is calculated using the [Aalen-Johansen method](#) to account for [competing outcomes](#). At time zero, 100% of patients are on support and as time passes, patients either experience death on support, transplant or explant without transplant. At any time point, the proportion alive on support plus the proportions experiencing each outcome will add up to 100%. Deaths after transplant are not counted and these patients are classed simply as transplanted. Any subsequent VAD support post-explant is not counted and any such patients are classed simply as explanted. If a patient is moved from one device to another (of any type) without a period free of support, they are counted as still on support.

For this cohort, at one year post- long-term implant, 63% of patients remained alive on support, 28% died on support, 7% received a heart transplant and 2% had their device explanted. At two years, the incidence of transplantation rose to 14%, however so did the incidence of death, to 36%, with the remaining 46% of patients still alive on support and 6% explanted. At three years, the incidence of death on support rose to 41%, the incidence of transplant rose to 20%, 6% had been explanted and 33% remained alive on support.

**Figure 4.3 Cumulative incidence of transplant, death and explant for adult patients implanted with a first long-term VAD, 1 April 2013 to 31 March 2017**



**Table 4.3a** and **Table 4.3b** shows the centre-specific one-year and three-year estimates for each competing outcome, respectively. The incidence of each outcome varies across centres.

<b>Table 4.3a Cumulative incidence of each outcome at 1 year, by centre, for adult patients implanted with a first long-term VAD, 1 April 2013 to 31 March 2017</b>					
Centre	Number of patients	Transplanted %	Explanted %	Alive on support %	Death on support %
Birmingham	57	5	4	67	25
Glasgow	3	0	0	100	0
Harefield	93	10	3	55	32
Manchester	46	2	0	83	15
Newcastle	91	9	1	57	33
Papworth	35	3	0	64	33
<b>Overall</b>	<b>325</b>	<b>7</b>	<b>2</b>	<b>63</b>	<b>28</b>

<b>Table 4.3b Cumulative incidence of each outcome at 3 years, by centre, for adult patients implanted with a first long-term VAD, 1 April 2013 to 31 March 2017</b>					
Centre	Number of patients	Transplanted %	Explanted %	Alive on support %	Death (before transplant) %
Birmingham	57	9	9	53	30
Glasgow	3	67	0	33	0
Harefield	93	18	6	39	37
Manchester	46	14	8	49	29
Newcastle	91	16	6	19	58
Papworth	35	49	0	10	41
<b>Overall</b>	<b>325</b>	<b>20</b>	<b>6</b>	<b>33</b>	<b>41</b>


#### 4.4 Survival on support

This section presents [Kaplan-Meier](#) estimates of [patient survival during long-term VAD support](#). All patients who received a [long-term VAD](#) were included, whether this was their first VAD or after a [short-term VAD](#). Survival time is calculated as the time on long-term VAD support only, and death on long-term support is the only event considered. Times were censored if the patient had their long-term VAD explanted, received a transplant from support, or were alive on support at last report. This differs from the analysis in [Section 4.5](#) which considers a patient's overall survival from implant and includes time after explant or transplant, as well as time on other subsequent devices.

The cohort analysed is those patients who received a first long-term device between 1 April 2013 and 31 March 2017 where information on survival post-implant is known. **Figure 4.4** shows the unadjusted survival curve on long-term support. **Table 4.4** shows the unadjusted centre-specific [survival on support rates](#) at 30 days, 1 year and 3 years respectively. The national [survival on support rates](#) were 87.8%, 72.7%, and 56.6% at 30 days, 1 year, and 3

years respectively. There was a significant difference between unadjusted survival on support at 3 years between centres (p=0.01).

**Figure 4.4 Patient survival during long-term VAD support for adult patients implanted 1 April 2013 – 31 March 2017**



**Table 4.4 Unadjusted survival during long-term VAD support, by centre, 1 April 2013 to 31 March 2017**

Centre	No. of patients	% 30 day survival (95% CI)		% 1 year survival (95% CI)		% 3 year survival (95% CI)	
Birmingham	64	92.1	(82.0 - 96.6)	77.2	(64.6 - 85.9)	71.7	(58.4 - 81.4)
Glasgow <sup>1</sup>	5	-	-	-	-	-	-
Harefield	113	84.7	(76.5 - 90.2)	70.0	(60.0 - 77.9)	61.0	(49.7 - 70.5)
Manchester	57	94.7	(84.6 - 98.3)	84.1	(71.7 - 91.4)	70.2	(51.6 - 82.8)
Newcastle	98	85.6	(76.9 - 91.2)	67.7	(57.1 - 76.3)	35.5	(23.4 - 47.7)
Papworth	37	89.2	(73.7 - 95.8)	69.3	(51.4 - 81.7)	45.3	(17.0 - 70.2)
Number at risk		318		237		63	
<b>Log-rank p-value</b>		<b>0.2</b>		<b>0.4</b>		<b>0.01</b>	
<b>UK</b>	<b>374</b>	<b>87.8</b>	<b>(84.1 - 90.8)</b>	<b>72.7</b>	<b>(67.8 - 77.1)</b>	<b>56.6</b>	<b>(50.1 - 62.5)</b>

<sup>1</sup> [Survival rates](#) for groups with fewer than 10 patients are not presented due to small numbers

## 4.5 Patient survival from implant

Overall survival rates from the point of first long-term VAD implant, not censored for transplant or explant, are presented in this section. Survival data from the [UK Transplant Registry](#) were incorporated, as was any additional survival time recorded on the [VAD Database](#) for patients who were explanted. Time on additional devices is also counted, so for example if a patient had a period of long-term support, then a period of short-term support, all this time is included. Times are censored if the patient was still alive at last known event or follow-up.

[Survival rates](#) are calculated using the [Kaplan-Meier method](#) and are based on those patients recorded as receiving a first device between 1 April 2013 and 31 March 2017 where information on survival post-implant is known.

In **Tables 4.5-4.7** and **Figures 4.5-4.7** the centre-specific [survival rates](#) for implants are presented for 30 days, 1 year and 3 years respectively. The national [survival rates](#) were 87.4%, 70.6%, and 52.1% at 30 days, 1 year, and 3 years respectively. The centre-specific rates are not adjusted for differences in risk between patients treated at different centres. These differences can be seen in **Table 4.8** which displays the baseline characteristics of the 325 patients included in this analysis. The survival rates are compared with the national rate and the uncertainty around this rate using [funnel plots](#) where outliers appear outside of the funnels; rates above the funnel are significantly high while rates below the funnel are significantly low. Rates for Glasgow are not included due to low numbers.



The [unadjusted](#) centre-specific 30-day [survival rates](#) for patients implanted in the recent period are shown in **Table 4.5** and **Figure 4.5**. The rate for Manchester was 95.7% which was between the upper 95% and 99.8% [confidence limits](#), indicating some evidence of a higher rate.


<b>Table 4.5 30-day patient survival rates after long-term VAD implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre</b>			
Centre	Number of patients	% 30-day survival (95% CI) <a href="#">Unadjusted</a>	
Birmingham	57	93.0	(82.4 - 97.3)
Glasgow <sup>1</sup>	3	-	-
Harefield	93	81.7	(72.2 - 88.2)
Manchester	46	95.7	(83.7 - 98.9)
Newcastle	91	83.5	(74.2 - 89.7)
Papworth	35	91.4	(75.7 - 97.2)
<b>UK</b>	<b>325</b>	<b>87.4</b>	<b>(83.3 - 90.5)</b>

	Centre has reached the lower 99.8% confidence limit
	Centre has reached the lower 95% confidence limit
	Centre has reached the upper 95% confidence limit
	Centre has reached the upper 98.8% confidence limit

<sup>1</sup> [Survival rates](#) for groups with fewer than 10 patients are not presented due to small numbers

**Figure 4.5 Unadjusted 30-day patient survival rates after long-term VAD implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre**



The [unadjusted](#) centre-specific 1-year [survival rates](#) are shown in **Table 4.6** and **Figure 4.6**. The centre-specific rates varied between 60.1% and 82.6% but apart from Manchester, for whom there was some evidence of a higher rate, all rates were consistent with the national rate.


<b>Table 4.6 1-year patient survival rates after long-term VAD implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre</b>			
Centre	Number of patients	% 1-year survival (95% CI) <a href="#">Unadjusted</a>	
Birmingham	57	75.4	(62.1 - 84.7)
Glasgow <sup>1</sup>	3	-	-
Harefield	93	66.2	(55.5 - 74.9)
Manchester	46	82.6	(68.2 - 90.9)
Newcastle	91	65.9	(55.2 - 74.6)
Papworth	35	68.6	(50.5 - 81.2)
<b>UK</b>	<b>325</b>	<b>70.6</b>	<b>(65.3 - 75.3)</b>

	Centre has reached the lower 99.8% confidence limit
	Centre has reached the lower 95% confidence limit
	Centre has reached the upper 95% confidence limit
	Centre has reached the upper 98.8% confidence limit

<sup>1</sup> [Survival rates](#) for groups with fewer than 10 patients are not presented due to small numbers

**Figure 4.6 Unadjusted 1-year patient survival rates after long-term VAD implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre**




The [unadjusted](#) centre-specific 3-year [survival rates](#) are shown in **Table 4.7** and **Figure 4.7**. The rate for Newcastle exceeded the lower 99.8% [confidence limit](#) for the national rate, indicating that their unadjusted rate was lower than the national rate. There was some evidence that the rate for Birmingham higher than average.

<b>Table 4.7 3-year patient survival rates after long-term VAD implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre</b>			
Centre	Number of patients	% 3-year survival (95% CI) <a href="#">Unadjusted</a>	
Birmingham	57	68.2	(54.3 - 78.6)
Glasgow <sup>1</sup>	3	-	-
Harefield	93	55.7	(44.4 - 65.6)
Manchester	46	62.6	(41.3 – 78.0)
Newcastle	91	36.0	(25.2 - 46.9)
Papworth	35	43.4	(25.1 - 60.4)
<b>UK</b>	<b>325</b>	<b>52.1</b>	<b>(45.9 - 57.9)</b>

Centre has reached the lower 99.8% confidence limit  
 Centre has reached the lower 95% confidence limit  
 Centre has reached the upper 95% confidence limit  
 Centre has reached the upper 98.8% confidence limit

<sup>1</sup> [Survival rates](#) for groups with fewer than 10 patients are not presented due to small numbers

**Figure 4.7 Unadjusted 3-year patient survival rates after long-term VAD implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre**



The demographic characteristics of the 325 patients in the survival from implant analysis are shown below in **Table 4.8** by centre and overall. Nationally, 84% of patients were male, the median age was 54 years and 67% of patients received a Heartware HVAD device. For some characteristics, due to rounding, percentages may not add up to 100.

<b>Table 4.8 Characteristics of patients in the long-term VAD patient survival from implant analysis, by centre</b>								
		Birmingham N (%)	Glasgow N (%)	Harefield N (%)	Manchester N (%)	Newcastle N (%)	Papworth N (%)	Total N (%)
Number of patients		57	3	93	46	91	35	<b>325</b>
Age at implant (years)	Median (IQR)	56 (50-62)	54 (28-56)	48 (38-57)	55 (45-57)	57 (44-61)	54 (46-59)	<b>54 (44-60)</b>
	Missing	0	0	0	0	0	0	<b>0</b>
Sex	Male	48 (84)	3 (100)	72 (77)	40 (87)	80 (88)	31 (89)	<b>274 (84)</b>
	Female	9 (16)	0 (0)	21 (23)	6 (13)	11 (12)	4 (11)	<b>51 (16)</b>
Primary disease	Dilated cardiomyopathy	23 (40)	1 (33)	67 (72)	21 (46)	51 (56)	22 (63)	<b>185 (57)</b>
	Ischaemic heart disease	28 (49)	0 (0)	21 (23)	19 (41)	31 (34)	8 (23)	<b>107 (33)</b>
	Congenital heart disease	1 (2)	0 (0)	0 (0)	0 (0)	7 (8)	0 (0)	<b>8 (2)</b>
	Hypertrophic cardiomyopathy	0 (0)	1 (33)	4 (4)	1 (2)	0 (0)	4 (11)	<b>10 (3)</b>
	Restrictive cardiomyopathy	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (3)	<b>1 (0)</b>
	Valvular heart disease	2 (4)	0 (0)	1 (1)	2 (4)	1 (1)	0 (0)	<b>6 (2)</b>
	Infiltrative heart muscle disease	0 (0)	0 (0)	0 (0)	0 (0)	1 (1)	0 (0)	<b>1 (0)</b>
	Other	2 (4)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	<b>4 (1)</b>
	Unknown	1 (2)	1 (33)	0 (0)	1 (2)	0 (0)	0 (0)	<b>3 (1)</b>
INTERMACS patient profile	1. Critical cardiogenic shock	7 (12)	0 (0)	27 (29)	2 (4)	9 (10)	0 (0)	<b>45 (14)</b>
	2. Progressive decline	20 (35)	2 (67)	42 (45)	9 (20)	27 (30)	19 (54)	<b>119 (37)</b>
	3. Stable but inotrope dependent	29 (51)	0 (0)	18 (19)	18 (39)	29 (32)	8 (23)	<b>102 (31)</b>
	4. Recurrent advanced heart failure	1 (2)	0 (0)	4 (4)	12 (26)	24 (26)	8 (23)	<b>49 (15)</b>
	5. Exertion intolerant	0 (0)	0 (0)	0 (0)	5 (11)	2 (2)	0 (0)	<b>7 (2)</b>
	6. Exertion limited	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	<b>0 (0)</b>
	7. Advanced NYHA Class 3	0 (0)	1 (33)	2 (2)	0 (0)	0 (0)	0 (0)	<b>3 (1)</b>
First VAD device name	Heartmate II	33 (58)	0 (0)	0 (0)	23 (50)	0 (0)	0 (0)	<b>56 (17)</b>
	Heartware	0 (0)	3 (100)	91 (98)	0 (0)	88 (97)	35 (100)	<b>217 (67)</b>
	Heartware MVAD	0 (0)	0 (0)	0 (0)	0 (0)	3 (3)	0 (0)	<b>3 (1)</b>
	HeartMate III	24 (42)	0 (0)	0 (0)	23 (50)	0 (0)	0 (0)	<b>47 (14)</b>
	Reliant Heart aVAD	0 (0)	0 (0)	2 (2)	0 (0)	0 (0)	0 (0)	<b>2 (1)</b>

## 4.6 TAH outcomes

**Table 4.9** shows the outcomes of the 21 patients who received a [TAH](#) as a bridge to transplant in the time period. All patients are considered, including those who received other MCS prior to the TAH, however one patient who received a TAH post-transplant is excluded. Three centres have used TAH in the time period. The 30-day post-implant [survival rate](#) for these patients was 60.0% (95% [confidence interval](#): 35.7 – 77.6%), however care should be used when interpreting this rate due to the small cohort the numbers are based on.

<b>Table 4.9 Outcomes of TAH recipients, by implant centre, 1 April 2008 to 31 March 2018</b>					
Centre	Number of patients N	Alive on support N (%)	Died without listing N (%)	Died with listing N (%)	Survived to transplant N (%)
Harefield	18	1 (6)	9 (50)	1 ( 6)	7 (39)
Newcastle	1	0 (0)	0 ( 0)	1 (100)	0 ( 0)
Papworth	2	0 (0)	1 (50)	0 ( 0)	1 (50)
<b>Overall</b>	<b>21</b>	<b>1 (5)</b>	<b>10 (48)</b>	<b>2 ( 10)</b>	<b>8 (38)</b>

# **ADULT SHORT-TERM DEVICES USED FOR BRIDGING**

**Activity**




## 5 Short-term bridging devices in adults


This section considers all patients who received [short-term](#) support as a bridge to heart transplantation. All figures and tables present information on a per implant basis as opposed to per patient, so if a single patient had more than one short-term device implant in the time period, each one is included.

**Figure 5.1** shows the total number of short-term bridging device implants in the last ten years nationally by device type ([ECMO](#) or short-term VAD). During 2017/2018 there were 115 implantations; 42 more than 2016/2017. Since 2014/2015 there have been more short-term VAD implants than [ECMO](#) procedures. **Figure 5.2** shows the trend per centre, with all centres apart from Papworth having their highest activity in 2017/2018. Last year's implant activity is shown by centre and device type in **Figure 5.3**. The highest number of [ECMO](#) procedures last year were performed by Newcastle.

**Figure 5.1** Number of adult short-term bridging device implants in the UK, by financial year and device type, 1 April 2008 to 31 March 2018



**Figure 5.2** Number of adult short-term bridging device implants in the UK, by financial year, centre and device type, 1 April 2008 to 31 March 2018





**Figure 5.3** Number of adult short-term bridging device implants in the UK, by centre and device type, 1 April 2017 to 31 March 2018





Figure 5.4 shows the [INTERMACS patient profile](#) at receipt of short-term support for patients implanted during 2017/2018. Most patients were profile 1 (critical cardiogenic shock).

**Figure 5.4** INTERMACS patient profile for all short-term bridging device implants in adult patients in the UK, 1 April 2017 to 31 March 2018



# **ADULT SHORT TERM DEVICES USED FOR BRIDGING**

**Patient Outcomes**



## 6 Outcomes of adult patients receiving short-term bridging devices


This section only considers patients who received a [short-term device](#) (including [ECMO](#)) as a bridge to transplant. Patients who received prior long-term support are excluded from this section, apart from [Section 6.4](#) which considers survival on short-term support. Patients with no follow-up information available are also excluded from this section as we cannot assume information about their time on support. Patients are analysed on a per-patient basis, as opposed to per implant.

### 6.1 Duration on support

**Table 6.1** shows the [median](#) duration on short-term support for patients implanted in a recent four year period, both nationally and by centre. The [medians](#) and [confidence intervals](#) are estimated using the [Kaplan-Meier method](#). Transplant, explant, death or transfer to a long-term device signify end of short-term support. If a patient went from [ECMO](#) to short-term VAD, all this time is counted. Nationally, the [median](#) time on support was 13 days and ranged from 6 days at Newcastle to 29 days at Manchester (log-rank  $p < 0.0001$ ).

<b>Table 6.1 Median duration on short-term bridging device support for adult patients implanted between 1 April 2013 and 31 March 2017, by centre</b>			
Centre	Number of patients	Time on support (days)	
		<a href="#">Median</a>	(95% <a href="#">confidence interval</a> )
Birmingham	49	15	10 - 20
Glasgow	25	14	3 - 25
Harefield	38	9	7 - 11
Manchester	55	29	20 - 38
Newcastle	33	6	4 - 8
Papworth	24	25	18 - 32
<b>Overall</b>	<b>224</b>	<b>13</b>	<b>10 - 16</b>


**Figure 6.1 Median duration on short-term bridging device support for adult patients implanted between 1 April 2013 and 31 March 2017**



## 6.2 Rate of transplant listing

**Figure 6.2** and **Table 6.2** show the rate of transplant listing for patients first implanted between 1 April 2013 and 31 March 2017, by centre. This includes listing on the super-urgent, urgent or non-urgent heart transplant lists (whichever occurred first) and considers time on long-term support if bridged to a long-term device. Overall, 17% of patients were listed prior to short-term implant, which was a smaller proportion than that observed for long-term implants (41%). This proportion ranged between 7% at Manchester to 32% at Glasgow (chi-square  $p=0.11$ ). The proportion listed within 1 month was 22% overall and differed across centres (chi-square  $p=0.02$ ).

**Figure 6.2 Heart transplant listing status with respect to short-term device implantation for adult patients receiving a first bridging device 1 April 2013 – 31 March 2017, by centre and overall**



**Table 6.2 Heart transplant listing status with respect to short-term device implantation for adult patients receiving a first bridging device 1 April 2013 – 31 March 2017, by centre and overall**


Centre	Number of patients N	Listed before VAD N (%)	Listed within 1 month N (%)	Not listed within 1 month N (%)	Died/explanted within 1 month without listing N (%)
Birmingham	49	10 (20)	13 (27)	9 (18)	17 (35)
Glasgow	25	8 (32)	5 (20)	5 (20)	7 (28)
Harefield	38	6 (16)	3 (8)	13 (34)	16 (42)
Manchester	55	4 (7)	10 (18)	22 (40)	19 (35)
Newcastle	33	4 (12)	7 (21)	0 (0)	22 (67)
Papworth	24	5 (21)	11 (46)	3 (13)	5 (21)
<b>Overall</b>	<b>224</b>	<b>37 (17)</b>	<b>49 (22)</b>	<b>52 (23)</b>	<b>86 (38)</b>

### 6.3 Competing outcomes

Whilst on short-term support, patients are susceptible to different outcomes. Death on support, transplant, transfer to long-term support and explant without transplant are all possible outcomes. **Figure 6.3** shows the [cumulative incidence](#) of each of these outcomes occurring from time of implantation, for the cohort of adult patients receiving a first short-term device between 1 April 2013 and 31 March 2017. This is calculated using the [Aalen-Johansen method](#) to account for [competing outcomes](#). At time zero, 100% of patients are on support and as time passes, patients either experience death on support, transplant, transferral to long-term support or explant without transplant. At any time point, the proportion alive on support plus the proportions experiencing each outcome will add up to 100%. Deaths after transplant are not counted and these patients are classed simply as transplanted. Any subsequent VAD support post-explant is not counted and any such patients are classed simply as explanted. If a patient is moved from one short-term device to another without a period free of support, they are counted as still on support.

For this cohort, one month after receipt of a short-term device, 17% were explanted, 25% of patients died on short-term support, 25% of patients remained alive on support, 15% received a transplant, and 19% were transferred to a long-term device. At two months, there was a small increase in the incidence of each of these events, leading to a reduction in the proportion that remained alive on support, down to 10%. The subsequent outcomes of those patients that were transferred to a long-term device are shown in [Section 6.6](#).

**Figure 6.3 Cumulative incidence of transplant, death, transferral to long-term device and explant for adult patients implanted with a first short-term bridging device, 1 April 2013 to 31 March 2017**



**Table 6.3** shows the centre-specific 30-day estimates for each competing outcome. The incidence of each outcome varies across centres, however the estimates are based on small groups of particularly high risk patients so it is expected that each individual patient's condition would have a strong influence on these statistics.


<b>Table 6.3 Cumulative incidence of each outcome at 30 days, by centre, for adult patients implanted with a first short-term bridging device, 1 April 2013 to 31 March 2017</b>						
Centre	Number of patients	Transplanted %	Transferred to LT device %	Explanted %	Alive on support %	Death on support %
Birmingham	49	27	12	6	16	39
Glasgow	25	20	0	20	36	24
Harefield	38	5	58	5	8	24
Manchester	55	9	9	7	49	25
Newcastle	33	0	21	70	6	3
Papworth	24	33	8	0	33	25
<b>Overall</b>	<b>224</b>	<b>15</b>	<b>17</b>	<b>19</b>	<b>25</b>	<b>25</b>

#### 6.4 Survival on support

This section presents [Kaplan-Meier](#) estimates of [patient survival during short-term VAD support](#). All patients who received a [short-term VAD](#) were included, whether this was their first VAD or not. Survival time is calculated as the time on short-term VAD support only, and death on short-term support is the only event considered. Times were censored if the patient had their short-term VAD explanted, received a transplant from support, or were alive on support at last report. This differs from the analysis in [Section 6.5](#) which considers a patient's overall survival from implant and includes time after explant or transplant, as well as time on other subsequent devices.

The cohort analysed is those patients who received a first short-term device between 1 April 2013 and 31 March 2017 where information on survival post-implant is known. **Figure 6.4** shows the unadjusted survival curve on short-term support. **Table 6.4** shows the unadjusted centre-specific [survival on support rates](#) at 30 days and 90 days respectively. The national [survival on support rates](#) were 65.1% and 44.7% at 30 days and 90 days respectively.

**Figure 6.4 Patient survival during short-term bridge to transplant support for adult patients implanted 1 April 2013 – 31 March 2017**



**Table 6.4 Unadjusted survival during short-term bridge to transplant support, by centre, 1 April 2013 to 31 March 2017**

Hospital	No. of patients	% 30 day survival (95% CI)		% 90 day survival (95% CI)	
Birmingham	52	53.8	(36.4 - 68.4)	32.3	( 8.5 - 59.5)
Glasgow	25	70.0	(44.3 - 85.5)	37.3	(13.4 - 61.6)
Harefield	43	50.9	(27.8 - 70.0)	50.9	(27.8 - 70.0)
Manchester	55	76.1	(60.9 - 86.1)	51.6	(29.7 - 69.7)
Newcastle	33	84.0	(52.5 - 95.4)	84.0	(52.5 - 95.4)
Papworth	25	66.9	(41.8 - 83.1)	53.5	(22.8 - 76.8)
Number at risk		66		13	
<b>Log-rank p-value</b>		<b>0.3</b>		<b>0.3</b>	
<b>UK</b>	<b>233</b>	<b>65.1</b>	<b>(57.0 - 72.1)</b>	<b>44.7</b>	<b>(33.1 - 55.7)</b>



## 6.5 Patient survival from implant

Overall survival rates from the point of first long-term VAD implant, not censored for transplant or explant, are presented in this section. Survival data from the [UK Transplant Registry](#) were incorporated, as was any additional survival time recorded on the [VAD Database](#) for patients who were explanted. Time on additional devices is also counted, so for example if a patient had a period of long-term support, then a period of short-term support, all this time is included. Times are censored if the patient was still alive at last known event or follow-up.

[Survival rates](#) are calculated using the [Kaplan-Meier method](#) and are based on those patients recorded as receiving a first device between 1 April 2013 and 31 March 2017 where information on survival post-implant is known.

In **Tables 6.5-6.7** and **Figures 6.5-6.7** the centre-specific [survival rates](#) for implants are presented for 30 days, 90 days and 1 year respectively. The centre-specific rates are not adjusted for potential differences in risk between patients treated at different centres. These differences can be seen in **Table 6.8** which displays the baseline characteristics of the 224 patients included in this analysis. The survival rates are compared with the national rate and the uncertainty around this rate using [funnel plots](#) where outliers appear outside of the funnels; rates above the funnel are significantly high while rates below the funnel are significantly low.


The [unadjusted](#) centre-specific 30-day [survival rates](#) for patients in the recent era are shown in **Table 6.5** and **Figure 6.5**. All of the centres were statistically consistent with the national rate of survival which was 63.0%.

<b>Table 6.5 30-day patient survival rates after short-term bridging device implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre</b>			
Centre	Number of patients	% 30-day survival (95% CI) <a href="#">Unadjusted</a>	
Birmingham	49	55.1	(40.2 - 67.7)
Glasgow	25	72.0	(50.1 - 85.5)
Harefield	38	57.6	(40.3 - 71.5)
Manchester	55	71.0	(56.5 - 81.4)
Newcastle	33	56.8	(33.5 - 74.6)
Papworth	24	70.8	(48.4 - 84.9)
<b>UK</b>	<b>224</b>	<b>63.0</b>	<b>(56.0 - 69.1)</b>

	Centre has reached the lower 99.8% confidence limit
	Centre has reached the lower 95% confidence limit
	Centre has reached the upper 95% confidence limit
	Centre has reached the upper 99.8% confidence limit

**Figure 6.5 Unadjusted 30-day patient survival rates after short-term bridging device implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre**




The [unadjusted](#) centre-specific 90-day [survival rates](#) are shown in **Table 6.6** and **Figure 6.6**. All of the centres were statistically consistent with the national rate of survival which was 52.8%.

<b>Table 6.6 90-day patient survival rates after short-term bridging device implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre</b>			
Centre	Number of patients	% 90-day survival (95% CI) <a href="#">Unadjusted</a>	
Birmingham	49	40.8	(27.1 - 54.1)
Glasgow	25	42.4	(22.8 - 60.7)
Harefield	38	57.6	(40.3 - 71.5)
Manchester	55	62.1	(47.0 - 74.0)
Newcastle	33	50.5	(27.3 - 69.8)
Papworth	24	66.7	(44.3 - 81.7)
<b>UK</b>	<b>224</b>	<b>52.8</b>	<b>(45.7 - 59.4)</b>

	Centre has reached the lower 99.8% confidence limit
	Centre has reached the lower 95% confidence limit
	Centre has reached the upper 95% confidence limit
	Centre has reached the upper 98.8% confidence limit

**Figure 6.6 Unadjusted 90-day patient survival rates after short-term bridging device implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre**




The [unadjusted](#) centre-specific 1-year [survival rates](#) are shown in **Table 6.7** and **Figure 6.7**. All of the centres were statistically consistent with the national rate of survival which was 44.8%.

<b>Table 6.7 1-year patient survival rates after short-term bridging device implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre</b>			
Centre	Number of patients	% 1-year survival (95% CI) <a href="#">Unadjusted</a>	
Birmingham	49	38.7	(25.2 - 51.9)
Glasgow	25	33.4	(15.7 - 52.1)
Harefield	38	40.3	(24.5 - 55.6)
Manchester	55	55.2	(40.1 – 68.0)
Newcastle	33	44.2	(21.7 - 64.6)
Papworth	24	58.3	(36.4 – 75.0)
<b>UK</b>	<b>224</b>	<b>44.8</b>	<b>(37.8 - 51.6)</b>

	Centre has reached the lower 99.8% confidence limit
	Centre has reached the lower 95% confidence limit
	Centre has reached the upper 95% confidence limit
	Centre has reached the upper 98.8% confidence limit

**Figure 6.7 Unadjusted 1-year patient survival rates after short-term bridging device implant for adult patients implanted 1 April 2013 – 31 March 2017, by centre**



The demographic characteristics of the 224 patients in the survival from implant analysis are shown below in **Table 6.8** by centre and overall. Nationally, 70% of patients were male, the median age was 44 years and 53% of patients received ECMO only. For some characteristics, due to rounding, percentages may not add up to 100.

<b>Table 6.8 Characteristics of patients in the short-term bridging survival from implant analysis, by centre</b>								
		Birmingham N (%)	Glasgow N (%)	Harefield N (%)	Manchester N (%)	Newcastle N (%)	Papworth N (%)	<b>Total N (%)</b>
Number of patients		49	25	38	55	33	24	<b>224</b>
Age at implant (years)	Median (IQR)	44 (32-54)	44 (36-49)	42 (30-52)	38 (28-52)	45 (35-55)	49 (29-54)	<b>44 (31-53)</b>
	Missing	0	0	0	0	0	0	<b>0</b>
Recipient sex	Male	32 (65)	16 (64)	24 (63)	40 (73)	23 (70)	21 (88)	<b>156 (70)</b>
	Female	17 (35)	9 (36)	14 (37)	15 (27)	10 (30)	3 (13)	<b>68 (30)</b>
Primary disease	Dilated cardiomyopathy	25 (51)	11 (44)	22 (58)	32 (58)	12 (36)	12 (50)	<b>114 (51)</b>
	Ischaemic heart disease	15 (31)	4 (16)	11 (29)	15 (27)	8 (24)	11 (46)	<b>64 (29)</b>
	Congenital heart disease	2 (4)	0 (0)	1 (3)	0 (0)	5 (15)	0 (0)	<b>8 (4)</b>
	Hypertrophic cardiomyopathy	1 (2)	2 (8)	1 (3)	0 (0)	0 (0)	0 (0)	<b>4 (2)</b>
	Valvular heart disease	2 (4)	2 (8)	1 (3)	2 (4)	0 (0)	0 (0)	<b>7 (3)</b>
	Infiltrative heart muscle disease	2 (4)	0 (0)	0 (0)	1 (2)	1 (3)	0 (0)	<b>4 (2)</b>
	Other	0 (0)	3 (12)	1 (3)	3 (5)	3 (9)	0 (0)	<b>10 (4)</b>
	Unknown	2 (4)	3 (12)	1 (3)	2 (4)	4 (12)	1 (4)	<b>13 (6)</b>
INTERMACS patient profile	1. Critical cardiogenic shock	36 (73)	12 (48)	34 (89)	48 (87)	16 (48)	14 (58)	<b>160 (71)</b>
	2. Progressive decline	12 (24)	12 (48)	1 (3)	6 (11)	17 (52)	9 (38)	<b>57 (25)</b>
	3. Stable but inotrope dependent	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)	1 (4)	<b>2 (1)</b>
	4. Recurrent advanced heart failure	1 (2)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)	<b>2 (1)</b>
	5. Exertion intolerant	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	<b>0 (0)</b>
	6. Exertion limited	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	<b>0 (0)</b>
	7. Advanced NYHA Class 3	0 (0)	0 (0)	1 (3)	0 (0)	0 (0)	0 (0)	<b>1 (0)</b>
	Unknown	0 (0)	0 (0)	1 (3)	1 (2)	0 (0)	0 (0)	<b>2 (1)</b>
First device name	Impella	7 (14)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	<b>7 (3)</b>
	Centrimag	25 (51)	14 (56)	9 (24)	35 (64)	1 (3)	15 (63)	<b>99 (44)</b>
	ECMO only	17 (35)	11 (44)	29 (76)	20 (36)	32 (97)	9 (38)	<b>118 (53)</b>

## 6.6 Bridge to long-term device

As seen in **Figure 6.3**, a proportion of patients that receive short-term support are later transferred to a long-term device. The median duration on short-term support for the subgroup of patients implanted with a short-term device between 1 April 2013 and 31 March 2017 and bridged to a long-term device was 9 days (95% [confidence interval](#): 5 - 13 days). Patient survival from the point of first short-term device implant, including time on long-term support and any subsequent treatment, is shown in **Figure 6.8** with the corresponding [survival rates](#) at 30 days, 90 days and 1 year in **Table 6.9**. Survival for this subgroup is superior to that of the full cohort of patients whose first device was a short-term device.

**Figure 6.8 Unadjusted patient survival from point of short-term device implant for adult patients implanted 1 April 2013 – 31 March 2017 and bridged to a long-term device**




Table 6.9 Patient survival rates after short-term device implant for adult patients bridged to a long-term device 1 April 2013 – 31 March 2017			
Number of patients	% 30-day survival (95% CI)	% 90-day survival (95% CI)	% 1-year survival (95% CI)
53	83.0 (69.9 - 90.8)	79.2 (65.7 - 87.9)	65.9 (51.5 - 77.0)

# **ADULT SHORT TERM DEVICES USED POST- HEART TRANSPLANT**

**Activity**




## 7 Short-term post-transplant devices in adults

This section considers all adult patients who received [short-term support](#) for [primary graft dysfunction \(PGD\)](#). All figures and tables in this section present information on a per implant basis as opposed to per patient; if a single patient had more than one short-term device implant for PGD each implant is included. Short-term devices used for [rejection](#) more than 30 days post-heart transplant are excluded (13 recorded in the time period) as are [long-term](#) devices used post-transplant (three Berlin Hearts by Newcastle and one [TAH](#) by Harefield).


**Figure 7.1** shows the total number of short-term device implants for PGD in the last ten years nationally by device type ([ECMO](#) or short-term VAD). During 2017/2018 there were 42 implantations, 5 more than 2016/2017 and 3.8 times higher than in 2008/2009. Since 2010/2011, [ECMO](#) has been more common than short-term VADs for treatment of PGD. **Figure 7.2** shows the trend per centre and **Figure 7.3** shows last year's activity by centre and device type, indicating that Newcastle, Papworth, and Birmingham had the highest activity in 2017/2018.

**Figure 7.1** Number of adult short-term device implants for PGD in the UK, by financial year and device type, 1 April 2008 to 31 March 2018






**Figure 7.2 Number of adult short-term device implants for PGD in the UK, by financial year, centre and device type, 1 April 2008 to 31 March 2018**



**Figure 7.3** Number of adult short-term device implants for PGD in the UK, by centre and device type, 1 April 2017 to 31 March 2018



# **ADULT SHORT-TERM DEVICES USED POST- HEART TRANSPLANT**

**Patient Outcomes**



## 8 Outcomes of adult patients receiving short-term devices for PGD


This section analyses patients on a per-patient basis, as opposed to per implant. If a patient was moved from one short-term device to another, this is counted as one observation.

### 8.1 Duration on support

**Table 8.1** shows the [median](#) duration on short-term support for patients implanted in a recent four year period, both nationally and by centre. The [medians](#) and [confidence intervals](#) are estimated using the [Kaplan-Meier method](#). This includes time spent on any short-term device post-transplant so if a patient went from [ECMO](#) to short-term VAD, all this time is counted. Nationally, the [median](#) time on support was 5 days and was similar across all centres.

<b>Table 8.1 Median duration on short-term device support for PGD for adult patients implanted between 1 April 2013 and 31 March 2017, by centre</b>			
Centre	Number of patients	Time of support (days)	
		<a href="#">Median</a>	(95% <a href="#">confidence interval</a> )
Birmingham	21	5	4 – 6
Glasgow	18	5	3 – 7
Harefield	20	7	6 – 8
Manchester	25	7	5 – 9
Newcastle	20	4	3 – 5
Papworth	8	3	0 – 6
<b>Overall</b>	<b>112</b>	<b>5</b>	<b>4 - 6</b>

**Figure 8.1 Median duration on short-term device support for PGD for adult patients implanted between 1 April 2013 and 31 March 2017**



## 8.2 Patient survival from implant

This analysis looks at the rate of survival from the point of first short-term device implant for PGD. This uses data from the [UK Transplant Registry](#) on post-transplant survival. [Survival rates](#) are calculated using the [Kaplan-Meier method](#) where times are censored if the patient was still alive at last known follow-up. The rates are estimated at 30 days, 90 days and 1 year and are based on the 112 patients recorded as receiving a short-term device for PGD between 1 April 2013 and 31 March 2017 where information on survival post-implant is known. Survival rates are given nationally and for individual centres. Note that the centre-specific rates are unadjusted for potential differences in risk between patients treated at different centres.

The [unadjusted](#) 30-day, 90-day and 1-year [survival rates](#) for patients in the time period are shown in **Tables 8.2, 8.3 and 8.4**, respectively. The national rates of survival were 62.7%, 56.2% and 47.0%, respectively. **Table 8.5** displays the transplant characteristics of the 112 patients included in this analysis.

**Table 8.2 30-day patient survival rates after short-term device implant for PGD for adult patients implanted 1 April 2013 – 31 March 2017, by centre**

Centre	Number of patients	Number of deaths	% 30-day survival (95% CI) <a href="#">Unadjusted</a>	
Birmingham	21	6	70.8	(46.2 - 85.7)
Glasgow	18	7	61.1	(35.3 - 79.2)
Harefield	20	11	40.0	(19.3 - 60.0)
Manchester	25	5	78.9	(56.4 - 90.6)
Newcastle	20	9	55.0	(31.3 - 73.5)
Papworth <sup>1</sup>	8	2	-	-
<b>UK</b>	<b>112</b>	<b>40</b>	<b>62.7</b>	<b>(52.9 - 71.0)</b>

<sup>1</sup> [Survival rates](#) for groups with fewer than 10 patients are not presented due to small numbers

**Table 8.3 90-day patient survival rates after short-term device implant for PGD for adult patients implanted 1 April 2013 – 31 March 2017, by centre**

Centre	Number of patients	Number of deaths	% 90-day survival (95% CI) <a href="#">Unadjusted</a>	
Birmingham	21	6	70.8	(46.2 - 85.7)
Glasgow	18	7	61.1	(35.3 - 79.2)
Harefield	20	16	20.0	(6.2 - 39.3)
Manchester	25	7	70.1	(47.2 - 84.5)
Newcastle	20	10	50.0	(27.1 - 69.2)
Papworth <sup>1</sup>	8	2	-	-
<b>UK</b>	<b>112</b>	<b>48</b>	<b>56.2</b>	<b>(46.4 - 64.9)</b>

<sup>1</sup> [Survival rates](#) for groups with fewer than 10 patients are not presented due to small numbers

**Table 8.4 1-year patient survival rates after short-term device implant for PGD for adult patients implanted 1 April 2013 – 31 March 2017, by centre**

Centre	Number of patients	Number of deaths	% 1-year survival (95% CI) <a href="#">Unadjusted</a>	
Birmingham	21	10	50.6	(27.7 - 69.7)
Glasgow	18	9	50.0	(25.9 - 70.1)
Harefield	20	16	20.0	(6.2 - 39.3)
Manchester	25	9	61.3	(38.8 - 77.7)
Newcastle	20	11	45.0	(23.1 - 64.7)
Papworth <sup>1</sup>	8	3	-	-
<b>UK</b>	<b>112</b>	<b>58</b>	<b>47.0</b>	<b>(37.4 - 56.0)</b>

<sup>1</sup> [Survival rates](#) for groups with fewer than 10 patients are not presented due to small numbers

The transplant characteristics of the 112 patients in the survival from implant analysis are shown below in **Table 8.5** by centre and overall. Nationally, 71% of patients were in hospital at transplant, the median age was 49 years and 94% of patients received ECMO only. For some characteristics, due to rounding, percentages may not add up to 100.

<b>Table 8.5 Characteristics of patients at time of transplant in the short-term PGD survival from implant analysis, by centre</b>								
		Birmingham N (%)	Glasgow N (%)	Harefield N (%)	Manchester N (%)	Newcastle N (%)	Papworth N (%)	<b>Total N (%)</b>
Number of patients		21	18	20	25	20	8	<b>112</b>
Urgency at transplant	Non-urgent	2 (10)	7 (39)	3 (15)	3 (12)	3 (15)	3 (38)	<b>21 (19)</b>
	Urgent	18 (86)	11 (61)	17 (85)	19 (76)	17 (85)	4 (50)	<b>86 (77)</b>
	Super-urgent	1 (5)	0 (0)	0 (0)	3 (12)	0 (0)	1 (13)	<b>5 (4)</b>
Recipient age at transplant (years)	Median (IQR)	51 (34-54)	49 (38-55)	50 (32-58)	51 (37-56)	44 (26-54)	46 (35-57)	<b>49 (34-55)</b>
	Missing	0	0	0	0	0	0	<b>0</b>
Diabetes at registration	No	17 (81)	13 (72)	19 (95)	22 (88)	19 (95)	6 (75)	<b>96 (86)</b>
	Yes	3 (14)	3 (17)	1 (5)	3 (12)	1 (5)	2 (25)	<b>13 (12)</b>
	Missing	1 (5)	2 (11)	0 (0)	0 (0)	0 (0)	0 (0)	<b>3 (3)</b>
Recipient primary disease at registration	Coronary heart disease	2 (10)	3 (17)	4 (20)	5 (20)	3 (15)	2 (25)	<b>19 (17)</b>
	Cardiomyopathy	12 (57)	8 (44)	7 (35)	13 (52)	10 (50)	3 (38)	<b>53 (47)</b>
	Congenital heart disease	2 (10)	0 (0)	2 (10)	0 (0)	4 (20)	1 (13)	<b>9 (8)</b>
	Graft failure/Rejection	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	<b>1 (1)</b>
	Other	5 (24)	7 (39)	5 (25)	7 (28)	3 (15)	2 (25)	<b>29 (26)</b>
	Missing	0 (0)	0 (0)	1 (5)	0 (0)	0 (0)	0 (0)	<b>1 (1)</b>
Recipient BMI (kg/m <sup>2</sup> )	Median (IQR)	26 (24-29)	27 (26-29)	24 (21-27)	24 (23-27)	26 (24-27)	29 (24-31)	<b>26 (23-29)</b>
	Missing	0	0	0	0	0	0	<b>0</b>
In hospital at transplant	No	4 (19)	6 (33)	2 (10)	3 (12)	11 (55)	5 (63)	<b>31 (28)</b>
	Yes	17 (81)	12 (67)	18 (90)	22 (88)	8 (40)	3 (38)	<b>80 (71)</b>
	Unknown	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)	<b>1 (1)</b>
If in hospital, recipient on inotropes	No	2 (12)	8 (67)	7 (39)	11 (50)	3 (38)	1 (33)	<b>32 (40)</b>
	Yes	15 (88)	4 (33)	11 (61)	11 (50)	5 (63)	2 (67)	<b>48 (60)</b>
If in hospital, recipient on VAD	None	9 (53)	7 (58)	11 (61)	13 (59)	5 (63)	2 (67)	<b>47 (59)</b>
	LVAD	2 (12)	2 (17)	5 (28)	1 (5)	3 (38)	0 (0)	<b>13 (16)</b>
	RVAD	2 (12)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	<b>2 (3)</b>
	BiVAD	4 (24)	3 (25)	2 (11)	8 (36)	0 (0)	1 (33)	<b>18 (23)</b>

**Table 8.5 Characteristics of patients at time of transplant in the short-term PGD survival from implant analysis, by centre**

		Birmingham	Glasgow	Harefield	Manchester	Newcastle	Papworth	Total
		N (%)	N (%)	N (%)	N (%)	N (%)	N (%)	N (%)
If in hospital, recipient on TAH	No	17 (100)	12 (100)	15 (83)	22 (100)	8 (100)	3 (100)	<b>77 (96)</b>
	Yes	0 (0)	0 (0)	3 (17)	0 (0)	0 (0)	0 (0)	<b>3 (4)</b>
If in hospital, recipient on ECMO	No	16 (94)	12 (100)	18 (100)	22 (100)	8 (100)	3 (100)	<b>79 (99)</b>
	Yes	1 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	<b>1 (1)</b>
If in hospital, recipient on IABP	No	16 (94)	8 (67)	17 (94)	21 (95)	7 (88)	3 (100)	<b>72 (90)</b>
	Yes	1 (6)	4 (33)	1 (6)	1 (5)	0 (0)	0 (0)	<b>7 (9)</b>
	Unknown	0 (0)	0 (0)	0 (0)	0 (0)	1 (13)	0 (0)	<b>1 (1)</b>
Recipient serum creatinine (umol/l)	Median (IQR)	112 (103-156)	87 (82-102)	94 (69-108)	81 (67-112)	116 (95-155)	86 (63-127)	<b>98 (74-122)</b>
	Missing	0	0	0	0	4	0	<b>4</b>
Donor cause of death	CVA	19 (90)	14 (78)	13 (65)	22 (88)	14 (70)	8 (100)	<b>90 (80)</b>
	Trauma	1 (5)	3 (17)	4 (20)	2 (8)	5 (25)	0 (0)	<b>15 (13)</b>
	Other	1 (5)	1 (6)	3 (15)	1 (4)	1 (5)	0 (0)	<b>7 (6)</b>
Donor age (years)	Median (IQR)	44 (39-50)	48 (40-53)	45 (27-52)	37 (29-48)	38 (26-47)	35 (25-46)	<b>43 (30-50)</b>
	Missing	0	0	0	0	0	0	<b>0</b>
Donor BMI (kg/m <sup>2</sup> )	Median (IQR)	28 (23-30)	28 (25-31)	26 (23-29)	25 (23-28)	29 (24-32)	24 (23-28)	<b>26 (23-30)</b>
	Missing	0	0	0	0	0	0	<b>0</b>
Donor past smoker	No	9 (43)	8 (44)	12 (60)	13 (52)	10 (50)	4 (50)	<b>56 (50)</b>
	Yes	11 (52)	10 (56)	7 (35)	11 (44)	10 (50)	4 (50)	<b>53 (47)</b>
	Unknown	1 (5)	0 (0)	1 (5)	1 (4)	0 (0)	0 (0)	<b>3 (3)</b>
Donor:Recipient sex mismatch	RF:DF	4 (19)	2 (11)	5 (25)	3 (12)	3 (15)	3 (38)	<b>20 (18)</b>
	RF:DM	1 (5)	1 (6)	3 (15)	2 (8)	1 (5)	0 (0)	<b>8 (7)</b>
	RM:DM	16 (76)	7 (39)	10 (50)	15 (60)	13 (65)	5 (63)	<b>66 (59)</b>
	RM:DF	0 (0)	8 (44)	2 (10)	5 (20)	3 (15)	0 (0)	<b>18 (16)</b>
Total ischaemia time (hours)	Median (IQR)	2.9 (2-3.3)	2.9 (2.6-3.4)	6.1 (4.9-7.1)	2.9 (2.5-3.2)	3 (2.3-3.3)	3.8 (3.3-4)	<b>3.1 (2.6-3.9)</b>
	Missing	2	0	2	0	2	0	<b>6</b>
First device name	Centrimag	5 (24)	1 (6)	0 (0)	0 (0)	0 (0)	1 (13)	<b>7 (6)</b>
	ECMO only	16 (76)	17 (94)	20 (100)	25 (100)	20 (100)	7 (88)	<b>105 (94)</b>



# **PAEDIATRIC DEVICES USED FOR BRIDGING**

**Activity**




## 9 Mechanical circulatory support in paediatrics

This section considers all paediatric (age less than 16 years) patients who received mechanical circulatory support as a bridge to heart transplantation between 1 April 2013 and 31 March 2018. Devices used post-transplant are excluded. All figures and tables in this section present information on a per implant basis as opposed to per patient, so if a single patient had more than one implant in the period, each one is included.


**Figure 9.1** shows the total number of bridging device implants each year nationally by device type ([long-term](#) and [short-term](#)). During 2017/2018 there were 28 implantations; 8 more than 2016/2017. The highest activity was recorded in 2014/2015. Overall, there were 126 implants, with long-term device implants making up 68%. **Figure 9.2** shows the trend per centre for the two paediatric centres. Last year's activity is shown by centre and device type in **Figure 9.3**.

**Figure 9.1** Number of paediatric bridging device implants in the UK, by financial year and device type, 1 April 2013 to 31 March 2018




Note: In the VAD Database, Berlin Heart Excor and Heartware are classed as “long-term” devices and Centrimag and ECMO only are classed as “short-term”. Through consultation with the paediatric centres, these classifications are understood to be inaccurate and misleading for paediatric patients. Therefore, future reports will seek to rectify this.

**Figure 9.2** Number of paediatric bridging device implants in the UK, by financial year, centre and device type, 1 April 2013 to 31 March 2018




**Figure 9.3** Number of paediatric bridging device implants in the UK, by centre and device type, 1 April 2017 to 31 March 2018



**Figure 9.4** shows the [INTERMACS patient profile](#) at implant for paediatric patients implanted during 2017/2018. Most patients implanted were either level 1 (critical cardiogenic shock) or level 2 (progressive decline).

**Figure 9.4 INTERMACS patient profile for all bridging devices used in paediatric patients in the UK, 1 April 2017 to 31 March 2018**



# **PAEDIATRIC DEVICES USED FOR BRIDGING**

## **Patient Outcomes**



## 10 Outcomes of paediatric patients receiving bridging devices

This section considers all paediatric patients who received any type of support for bridging. If a patient was moved from a short-term device to a long-term device, for example, the entire time they were on support is considered. Patients are analysed on a per-patient basis, as opposed to per implant.

### 10.1 Duration on support

**Table 10.1** shows the [median](#) duration on support for patients implanted in a recent four year period, both nationally and by centre. The [medians](#) and [confidence intervals](#) are estimated using the [Kaplan-Meier method](#) since not all patients may have come to the end of support and this method allows these (censored) patients to be included in the analysis. Transplant, explant or death signify end of support. Nationally, the [median](#) time on support was 59 days.

<b>Table 10.1 Median duration on support for paediatric patients implanted with a bridging device between 1 April 2013 and 31 March 2017, by centre</b>			
Centre	Number of patients	Time on support (days)	
		<a href="#">Median</a>	(95% <a href="#">confidence interval</a> )
Great Ormond Street	41	97	64 - 130
Newcastle	44	31	25 - 37
<b>Overall</b>	<b>85</b>	<b>59</b>	<b>33 - 85</b>


**Figure 10.1 Median duration on support for paediatric patients implanted with a bridging device between 1 April 2013 and 31 March 2017**



## 10.2 Rate of transplant listing

**Figure 10.2** and **Table 10.2** show the rate of transplant listing for patients implanted between 1 April 2013 and 31 March 2017 by centre. This includes listing on the urgent or non-urgent heart transplant lists (whichever occurred first). Overall, 73% of patients were listed prior to implant, with a further 19% listed after implant and 8% who had died or been explanted within one-year post-implant without being listed.

**Figure 10.2 Heart transplant listing status with respect to bridging device implantation for paediatric patients implanted 1 April 2013 – 31 March 2017, by centre and overall**



<b>Table 10.2 Heart transplant listing status with respect to bridging device implantation for paediatric patients implanted 1 April 2013 – 31 March 2017, by centre and overall</b>					
Centre	Number of patients N	Listed before VAD implant N (%)	Listed within 1 year N (%)	Not listed within 1 year N (%)	Died/explanted within 1 year without listing N (%)
Great Ormond Street	41	33 (80)	6 (15)	0 (-)	2 (5)
Newcastle	44	29 (66)	10 (23)	0 (-)	5 (11)
<b>Overall</b>	<b>85</b>	<b>62 (73)</b>	<b>16 (19)</b>	<b>0 (-)</b>	<b>7 (8)</b>




### 10.3 Competing outcomes

Whilst on short-term support, patients are susceptible to different outcomes. Death on support, transplant and explant without transplant (with or without recovery) are all possible outcomes. **Figure 10.3** shows the [cumulative incidence](#) of each of these outcomes occurring from time of implantation, for the cohort of paediatric patients receiving a first device between 1 April 2013 and 31 March 2017. This is calculated using the [Aalen-Johansen method](#) to account for [competing outcomes](#). At time zero, 100% of patients are on support and as time passes, patients either experience death on support, transplant or explant without transplant. At any time point, the proportion alive on support plus the proportions experiencing each outcome will add up to 100%. Deaths after transplant are not counted and these patients are classed simply as transplanted. Any subsequent VAD support post-explant is not counted and any such patients are classed simply as explanted. If a patient is moved from one device to another (of any type) without a period free of support, they are counted as still on support.

For this cohort, one month after receipt of a device, 61% of patients remained alive on support, 28% received a heart transplant, 5% died on support and 6% had their device explanted. At three months, the incidence of transplantation rose to 46%, the incidence of death rose slightly, to 7%, and the proportion explanted became 9%, leaving 38% left on support.

**Figure 10.3** Cumulative incidence functions for transplant, death and explant for paediatric patients receiving a bridging device, 1 April 2013 to 31 March 2017



**Table 10.3** shows the centre-specific 90-day estimates for each competing outcome. A slightly higher proportion of patients had received a transplant by 90 days at Newcastle (50%) compared with Great Ormond Street (41%).

<b>Table 10.3 Cumulative incidence of each outcome at 90 days, by centre, for paediatric patients implanted with a first bridging device, 1 April 2013 to 31 March 2017</b>					
Centre	Number of patients	Transplanted %	Explanted %	Alive on support %	Death on support %
Great Ormond Street	41	41	5	49	5
Newcastle	44	50	14	27	9
<b>Overall</b>	<b>85</b>	<b>46</b>	<b>9</b>	<b>38</b>	<b>7</b>

#### 10.4 Patient survival from implant

Overall survival rates from the point of first device implant, not censored for transplant or explant, are presented in this section. Survival data from the [UK Transplant Registry](#) were incorporated, as was any additional survival time recorded on the [VAD Database](#) for patients who were explanted. Time on additional devices is also counted, so for example if a patient had a period of long-term support, then a period of short-term support, all this time is included. Times are censored if the patient was still alive at last known event or follow-up.

[Survival rates](#) are calculated using the [Kaplan-Meier method](#). The rates are estimated at 30 days, 90 days and 1 year and are based on the 85 patients recorded as receiving a bridging device between 1 April 2013 and 31 March 2017 where information on survival post-implant is known. Survival rates are given nationally and for individual centres. The centre-specific rates are unadjusted for potential differences in risk between patients treated at different centres.

The [unadjusted](#) 30-day, 90-day and 1-year [survival rates](#) for patients in the period are shown in **Tables 10.4, 10.5 and 10.6**, respectively. The national rate of survival at each time point was 91.8%, 87.0% and 79.7%, respectively. **Table 10.7** displays the baseline characteristics of the 85 patients included in this analysis.

**Table 10.4 30-day patient survival rates after bridging device implant for paediatric patients implanted 1 April 2013 – 31 March 2017, by centre**

Centre	Number of patients	Number of deaths	% 30-day survival (95% CI) <a href="#">Unadjusted</a>	
Great Ormond Street	41	2	95.1	(81.9 - 98.8)
Newcastle	44	5	88.6	(74.8 - 95.1)
<b>UK</b>	<b>85</b>	<b>7</b>	<b>91.8</b>	<b>(83.5 – 96.0)</b>

**Table 10.5 90-day patient survival rates after bridging device implant for paediatric patients implanted 1 April 2013 – 31 March 2017, by centre**

Centre	Number of patients	Number of deaths	% 90-day survival (95% CI) <a href="#">Unadjusted</a>	
Great Ormond Street	41	4	90.2	(76.1 - 96.2)
Newcastle	44	6	84.0	(69.4 – 92.0)
<b>UK</b>	<b>85</b>	<b>10</b>	<b>87.0</b>	<b>(77.8 - 92.6)</b>

**Table 10.6 1-year patient survival rates after bridging device implant for paediatric patients implanted 1 April 2013 – 31 March 2017, by centre**

Centre	Number of patients	Number of deaths	% 1-year survival (95% CI) <a href="#">Unadjusted</a>	
Great Ormond Street	41	5	87.8	(73.2 - 94.7)
Newcastle	44	12	72.3	(56.4 - 83.2)
<b>UK</b>	<b>85</b>	<b>17</b>	<b>79.7</b>	<b>(69.4 - 86.9)</b>

The demographic characteristics of the 85 patients in the survival from implant analysis are shown below in **Table 10.7** by centre and overall. Nationally, 52% of patients were female, the median age was 3 years and 46% of patients received a Berlin Heart Excor device. For some characteristics, due to rounding, percentages may not add up to 100.

<b>Table 10.7 Characteristics of patients in the paediatric survival from implant analysis, by centre</b>				
		Great Ormond Street N (%)	Newcastle N (%)	Total N (%)
Number of patients		41	44	<b>85</b>
Age at implant (years)	Median (IQR)	5 (2-11)	2 (0-8)	<b>3 (0-10)</b>
	Missing	0	0	<b>0</b>
Sex	Male	17 (41)	24 (55)	<b>41 (48)</b>
	Female	24 (59)	20 (45)	<b>44 (52)</b>
Primary disease	Dilated cardiomyopathy	30 (73)	32 (73)	<b>62 (73)</b>
	Congenital heart disease	0 (0)	8 (18)	<b>8 (9)</b>
	Hypertrophic cardiomyopathy	2 (5)	0 (0)	<b>2 (2)</b>
	Restrictive cardiomyopathy	3 (7)	2 (5)	<b>5 (6)</b>
	Other	6 (15)	2 (5)	<b>8 (9)</b>
INTERMACS patient profile	1. Critical cardiogenic shock	7 (17)	37 (84)	<b>44 (52)</b>
	2. Progressive decline	25 (61)	6 (14)	<b>31 (36)</b>
	3. Stable but inotrope dependent	7 (17)	1 (2)	<b>8 (9)</b>
	4. Recurrent advanced heart failure	1 (2)	0 (0)	<b>1 (1)</b>
	5. Exertion intolerant	0 (0)	0 (0)	<b>0 (0)</b>
	6. Exertion limited	1 (2)	0 (0)	<b>1 (1)</b>
	7. Advanced NYHA Class 3	0 (0)	0 (0)	<b>0 (0)</b>
First VAD device name	Berlin Heart Excor	25 (61)	14 (32)	<b>39 (46)</b>
	Heartware	7 (17)	13 (30)	<b>20 (24)</b>
	Centrimag	4 (10)	5 (11)	<b>9 (11)</b>
	Centrimag with BH cannulae	0 (0)	11 (25)	<b>11 (13)</b>
	ECMO only	5 (12)	1 (2)	<b>6 (7)</b>

# APPENDIX



## A1: Data

The cohort of patients in this report varies by section and type of analysis. **Tables A1.1** and **A1.2** summarise the number of adult and paediatric patients/implants (respectively) in each cohort and the section this applies to.

Table A1.1 Data analysed for adults			
Time period	Report Section	Exclusion criteria	No. implants/patients
<b>Adult – Long-term bridging</b>			
1 April 2008 – 31 March 2018	<ul style="list-style-type: none"> <li>Introduction/Activity</li> </ul>	None	863 (implants)
1 April 2013 – 31 March 2017	<ul style="list-style-type: none"> <li>Duration on support</li> <li>Rate of transplant listing</li> <li>Competing outcomes</li> <li>Patient survival from implant</li> </ul>	<ul style="list-style-type: none"> <li><a href="#">TAH</a> and <a href="#">pulsatile devices</a></li> <li>Patients who had a previous short-term device</li> <li>Patients with no follow-up information</li> </ul>	325 (patients)
1 April 2013 – 31 March 2017	<ul style="list-style-type: none"> <li>Survival on support</li> </ul>	<ul style="list-style-type: none"> <li><a href="#">TAH</a> and <a href="#">pulsatile devices</a></li> <li>Patients with no follow-up information</li> </ul>	374 (patients)
1 April 2008 – 31 March 2018	<ul style="list-style-type: none"> <li>TAH outcomes</li> </ul>	<ul style="list-style-type: none"> <li>Patients who received a TAH post-transplant</li> </ul>	21 (patients)
<b>Adult – Short-term bridging</b>			
1 April 2008 – 31 March 2018	<ul style="list-style-type: none"> <li>Introduction/Activity</li> </ul>	None	525 (implants)
1 April 2013 – 31 March 2017	<ul style="list-style-type: none"> <li>Duration on support</li> <li>Rate of transplant listing</li> <li>Competing outcomes</li> <li>Patient survival from implant</li> </ul>	<ul style="list-style-type: none"> <li>Patients who had a previous long-term device</li> <li>Patients with no follow-up information</li> </ul>	224 (patients)
1 April 2013 – 31 March 2017	<ul style="list-style-type: none"> <li>Survival on support</li> </ul>	<ul style="list-style-type: none"> <li>Patients with no follow-up information</li> </ul>	233 (patients)
1 April 2013 – 31 March 2017	<ul style="list-style-type: none"> <li>Bridge to long-term device</li> </ul>	<ul style="list-style-type: none"> <li>Patients who had a previous long-term device</li> <li>Patients with no follow-up information</li> </ul>	53 (patients)
<b>Adult – Short-term post-transplant</b>			
1 April 2008 – 31 March 2018	<ul style="list-style-type: none"> <li>Introduction/Activity</li> </ul>	<ul style="list-style-type: none"> <li>Implants for <a href="#">rejection</a></li> <li>Long-term devices used post-transplant</li> </ul>	239 (implants)
1 April 2013 – 31 March 2017	<ul style="list-style-type: none"> <li>Duration on support</li> <li>Patient survival from implant</li> </ul>	<ul style="list-style-type: none"> <li>Implants for <a href="#">rejection</a></li> <li>Long-term devices used post-transplant</li> <li>Patients with no follow-up information</li> </ul>	112 (patients)

Table A1.2 Data analysed for paediatrics			
Time period	Report Section	Exclusion criteria	No. implants/patients
<b>Paediatric – Bridging devices</b>			
1 April 2013 – 31 March 2018	<ul style="list-style-type: none"> <li>• Introduction/Activity</li> </ul>	None	126 (implants)
1 April 2013 – 31 March 2017	<ul style="list-style-type: none"> <li>• Duration on support</li> <li>• Rate of transplant listing</li> <li>• Competing outcomes</li> <li>• Patient survival from implant</li> </ul>	<ul style="list-style-type: none"> <li>• Patients with no follow-up information</li> </ul>	85 (patients)

**Limitations and classifications:**

- BiVADs are counted as one implant.
- “Bridging” includes devices entered onto the VAD Database under “bridge to decision” as well as “bridge to transplant”.
- Patients who received concurrent short-term support with long-term support are classed simply as long-term device recipients.
- Patients who received concurrent ECMO support with a VAD are classed simply as VAD recipients.
- Any paediatric (age<16) activity reported by an adult only centre is presented in the adult sections.

**Table A1.3** details the device history of patients reported as receiving a bridging device between 1 April 2008 and 31 March 2018 and the section of the report each type of patient is included in. For example, 619 adult patients received a single long-term device implant, of which 619 are included in the activity section of the long-term part of the report, and 594 are included in the outcome section (since 25 pulsatile device recipients are excluded).

**Table A1.4** shows the same information for post-transplant device recipients.

**Table A1.3 Device history of adult and paediatric patients receiving bridging device implants, 1 April 2008 – 31 March 2018, and the section of the report patients are included in**

Age group	Device history	No. patients	Long-term section		Short-term section	
			Activity	Outcome	Activity	Outcome
Adult	LT	619	619	594		
	LT-ECMO	8	8	8	8	
	LT-ECMO-LT	1	1	1	1	
	LT-ECMO-ST-LT	1	1	1	1	
	LT-LT	43	43	39		
	LT-LT-ECMO	1	1	1	1	
	LT-LT-LT	1	1	1		
	LT-LT-LT-LT	1	1	1		
	LT-LT-ST	1	1	1	1	
	LT-LT-ST-LT	1	1	1	1	
	LT-ST	5	5	5	5	
	LT-ST-LT	1	1	1	1	
	LT-TAH	2	2	2		
	LT/ECMO	1	1	1	1	
	LT/LT	1	1	1		
	LT/LT-ECMO	1	1	1	1	
	LT/LT-LT/ST	1	1	1	1	
	LT/ST <sup>1</sup>	1			1	
	TAH	11	11	11		
	ST	175			175	175
	ST-ECMO	3			3	3
	ST-ECMO-ST-LT	1		1	1	1
	ST-LT	31		31	31	31
	ST-LT-LT	3		3	3	3
	ST-ST	3			3	3
	ST-ST-LT	2		2	2	2
	ST-TAH	2		2	2	2
	ECMO	101			101	101
	ECMO-ECMO	3			3	3
	ECMO-LT	37		37	37	37
	ECMO-LT-ECMO	1		1	1	1
	ECMO-LT-LT	1		1	1	1
	ECMO-ST	42			42	42
ECMO-ST-LT	10		10	10	10	
ECMO-ST/LT	1		1	1	1	
ECMO-TAH	6		6	6	6	
ECMO/ECMO	2			2	2	
ECMO/ECMO-ST	1			1	1	
ECMO/LT	3		3	3	3	
ECMO/ST	1			1	1	
<b>Total</b>	<b>1130</b>		<b>798</b>	<b>677</b>	<b>452</b>	
		<b>No. patients</b>	<b>Paediatric section</b>			
			<b>Activity</b>	<b>Outcome</b>		
Paediatric	LT	69	69	69		
	LT-LT	1	1	1		
	LT/ECMO-LT	1	1	1		
	LT/LT	1	1	1		
	ST	22	22	22		
	ST-LT	3	3	3		
	ST-LT-ST-LT	1	1	1		
	ST-LT/ST	1	1	1		
	ST-ST	1	1	1		
	ST/ST	1	1	1		
	ECMO	1	1	1		
	ECMO-LT	5	5	5		
<b>Total</b>	<b>107</b>		<b>107</b>	<b>107</b>		

<sup>1</sup> Long-term implant happened prior to reporting period

LT=Long-Term, ST=Short-Term, ECMO=Extra Corporeal Membrane Oxygenation, TAH= Total Artificial Heart

LT-ST indicates that a patient received a long-term device and then a short-term device immediately following explantation of a long-term device

LT/ST indicates that a patient received a long-term device which was explanted and then a short-term device after a period of no support

Shading indicates exclusion of patients with a particular device history from a given section



**Table A1.4 Device history of adult and paediatric patients receiving post-transplant device implants, 1 April 2008 – 31 March 2018, and the section of the report patients are included in**

Age group	Device history	No. patients	PGD section		Rejection <sup>1</sup>
			Activity	Outcome	
Adult	LT	3			
	TAH/ECMO	1	1	1	
	ST	33	33	33	
	ST-ECMO	1	1	1	
	ST-ST	1			1
	ST-ST-ECMO	1			1
	ST/ECMO	1	1	1	1
	ECMO	149	147	147	2
	ECMO-ECMO-ST	1	1	1	
	ECMO-ST	15	14	14	1
	ECMO-ST/ECMO	1	1	1	
	ECMO/ECMO	7	6	6	2
	ECMO/ECMO/ECMO/ECMO	1	1	1	
	ECMO/ST	2	2	2	
	<b>Total</b>	<b>217</b>	<b>208</b>	<b>208</b>	<b>8</b>
Paediatric	LT	2			2
	<b>Total</b>	<b>2</b>			<b>2</b>

<sup>1</sup> Included in text only

LT=Long-Term, ST=Short-Term, ECMO=Extra Corporeal Membrane Oxygenation, TAH= Total Artificial Heart  
 LT-ST indicates that a patient received a long-term device and then a short-term device immediately following explantation of a long-term device

LT/ST indicates that a patient received a long-term device which was explanted and then a short-term device after a period of no support

Shading indicates exclusion of patients with a particular device history from a given section

## A2: Methods

### Analysis of geographical variation in MCS rates

Patients were assigned to Strategic Health Authorities (SHA) in England or country for Wales, Scotland and Northern Ireland using their postcode of residence, as reported at implant. Patients were only counted once regardless of how many devices they received in the period. The number of patients receiving a device per million population (pmp) of SHA/country was obtained using mid-2016 population estimates based on the Office for National Statistics (ONS) 2011 Census figures (denominator). No SHA age- or sex-specific standardisation of rates was performed when calculating the systematic component of variation. The MCS rates pmp were categorised into four groups – low, low-medium, medium-high and high – based on the quartiles of their distribution and visualised in a map using contrasting colours.

### Systematic component of variation

For a given individual who is a resident in a given English Strategic Health Authority (SHA), provision of a bridging device is modelled as a Bernoulli trial. At the whole area level, this becomes a Binomial process which can be approximated by a Poisson distribution when rare events are modelled.

To allow for the possibility that, even after allowing for area-specific Poisson rates, area differences remain, we introduce an additional multiplicative rate factor which varies from area to area. We postulate a non-parametric distribution for the multiplicative factor, with variance  $\sigma^2$ . If the factor is one for all areas, then area differences are fully explained by the area-specific Poisson rate. If the factor varies with a nonzero variance,  $\sigma^2$ , then we conclude that there are unexplained area differences.

The systematic component of variation (SCV; McPherson *et al.*, *N Engl J Med* 1982, **307**: 1310-4) is the moment estimator of  $\sigma^2$ . Under the null hypothesis of homogeneity across areas, the SCV would be zero. The SCV, therefore, allows us to detect variability across areas beyond that expected by chance; the larger the SCV, the greater the evidence of systematic variation across areas.

### Unadjusted survival rates

The [Kaplan-Meier method](#) is used to estimate [unadjusted](#) patient [survival rates](#). Patients can be included in this method of analysis irrespective of the length of follow-up recorded. If a patient is alive at the end of the follow-up then information about the survival of the patient is censored, which means they have not yet experienced the outcome of death.

### Funnel plots

The funnel plot is a graphical method to show how consistent the [survival rates](#) of the different centres are with the national rate. The graph shows for each centre a survival rate plotted against the number of procedures undertaken, with the national rate and [confidence limits](#) around this national rate superimposed. In this report, 95% and 99.8% [confidence limits](#) were used. Centres that lie within the [confidence limits](#) have survival rates that are statistically consistent with the national rate. When a centre is close to or outside the limits, this is an indication that the centre may have a rate that is different from the national rate.

### **A3: Glossary of terms**

#### **Aalen-Johansen method**

A method for calculating the cause-specific [cumulative incidence](#) which allows for patients experiencing one of a set of outcomes where each outcome may preclude or change the probability of a patient experiencing any of the others (“competing risks”). It allows for patients with incomplete follow-up to be included as per the [Kaplan-Meier method](#).

#### **Competing outcomes**

A situation when patients or subjects can experience one or more events or outcomes which ‘compete’ with the outcome of interest. For instance, when the event of interest is death on VAD support, receiving a transplant or having ones’ device explanted and recovering are competing outcomes. Generally, the competing outcomes hinder the observation of the event of interest or modify the chance that this event occurs.

#### **Confidence interval (CI)**

When an estimate of a quantity such as a [survival rate](#) is obtained from data, the value of the estimate depends on the set of patients whose data were used. If, by chance, data from a different set of patients had been used, the value of the estimate may have been different. There is therefore some uncertainty linked with any estimate. A confidence interval is a range of values whose width gives an indication of the uncertainty or precision of an estimate. The number of patients analysed influences the width of a confidence interval. Smaller data sets tend to lead to wider confidence intervals compared to larger data sets. Estimates from larger data sets are therefore more precise than those from smaller data sets. Confidence intervals are calculated with a stated probability, usually 95%. We then say that there is a 95% chance that the confidence interval includes the true value of the quantity we wish to estimate.

#### **Confidence limit**

The upper and lower bounds of a confidence interval.

#### **Continuous-flow device**

An electrically driven rotary pump that pumps blood continuously throughout the cardiac cycle.

#### **Cumulative incidence**

The probability of an event (death, transplant or explant in this context) occurring before a particular point in time.

#### **ECMO**

Extra Corporeal Membrane Oxygenation. The term ECMO in this report is used to describe veno-arterial (VA) ECMO, rather than veno-venous (VV) ECMO.

#### **INTERMACS patient profile**

**Level 1:** [Critical cardiogenic shock](#) describes the patient who is “crashing and burning”; in which patients have life-threatening hypotension despite rapidly escalating inotropic support, occasionally with IABP placement as well, with critical organ hypoperfusion often confirmed by worsening acidosis and lactate levels. Patients may have less than 24 hours survival expected without mechanical support.

**Level 2:** [Progressive decline](#) describes the patient who has been demonstrated “dependent” on inotropic support but nonetheless shows signs of continuing

deterioration in nutrition, renal function, fluid retention, or other major status indicator. Level 2 can also describe a patient with refractory volume overload, perhaps with evidence of impaired perfusion, in whom inotropic infusions *cannot be maintained* due to tachyarrhythmia, clinical ischemia, or other intolerance.

**Level 3:** Stable but inotrope dependent describes the patient who is clinically stable on mild–moderate doses of intravenous inotropes after repeated documentation of failure to wean without symptomatic hypotension, worsening symptoms, or progressive organ dysfunction (usually renal). It is critical to monitor nutrition, renal function, fluid balance, and overall status carefully in order to distinguish between patients who are truly stable at Level 3 and those who have unappreciated decline rendering them Level 2.

**Level 4:** is the level of “recurrent” rather than “refractory” decompensation. After interventions such as hospitalization for intravenous diuretics, these patients can be stabilized briefly on an oral regimen at close to normal volume status. However, they experience brief relapses into fluid retention. These patients should be carefully considered for more intensive management and surveillance programs, by which some may be recognized to have poor compliance that would compromise outcomes with any therapy.

**Level 5:** describes patients who are comfortable at rest but are exercise intolerant for most activity, living predominantly within the house or housebound. They have no congestive symptoms, but may have chronically elevated volume status, frequently with renal dysfunction, and may be characterized as housebound.

**Level 6:** is a similar patient who is generally without any evidence of fluid overload and able to do some mild activity. Activities of daily living are comfortable and minor activities outside the home such as visiting friends or going to a restaurant can be performed, but fatigue results within a few minutes or any meaningful physical exertion.

**Level 7:** describes patients who are clinically stable with a reasonable level of comfortable activity, despite history of previous decompensation that is not recent. Any decompensation requiring intravenous diuretics or hospitalization within the previous 2 weeks should make the person a Level 4 or lower.

*ISHLT Mechanically Assisted Circulatory Support Registry Users' Guide (2012)*. Birmingham, AL ([http://www.isHLT.org/ContentDocuments/IMACS\\_Users\\_Guide\\_Final\\_032414.pdf](http://www.isHLT.org/ContentDocuments/IMACS_Users_Guide_Final_032414.pdf))

### **Kaplan-Meier method**

A method that allows patients with incomplete follow-up information to be included in estimating survival rates and other time related statistics such as median duration on support. For example, when estimating one year patient survival rates, a patient may be followed up for only nine months before they relocate. If we calculated a crude survival estimate using the number of patients who survived for at least a year, this patient would have to be excluded as it is not known whether or not the patient was still alive at one year after VAD implantation. The Kaplan-Meier method allows information about such patients to be used for the length of time that they are followed-up, when this information would otherwise be discarded. Such instances of incomplete follow-up are not uncommon and the Kaplan-Meier method allows the computation of estimates that are more meaningful in these cases.

### **Long-term (LT) devices**

Long-term devices are implantable and intended to support the patient for years. Patients can be discharged from hospital with a LT device. Most LT devices are [continuous-flow](#) devices but some are [pulsatile](#).

### **MCS**

Mechanical Circulatory Support.

### **Median**

The midpoint in a series of numbers, so that half the data values are larger than the median, and half are smaller.

### **Patient survival rate**

The estimated percentage of patients who are still alive. This is usually specified for a given time period after implant. For example, a 1 year patient survival rate is the estimated percentage of patients who are still alive 1 year after their first device implant.

### **Primary graft dysfunction**

In this report primary graft dysfunction (PGD) is defined as all VADs and ECMOs used for graft failure within 30 days of heart transplantation.

### **Pulsatile device**

A device that mimics the natural pulsing action of the heart.

### ***p* value**

In the context of comparing listing rates across centres, as an example, the *p* value is the probability that the differences observed in the rates across centres occurred by chance. As this is a probability, it takes values between 0 and 1. If the *p* value is small, say less than 0.05, this implies that the differences are unlikely to be due to chance and there may be some identifiable cause for these differences. If the *p* value is large, say greater than 0.1, then it is quite likely that any differences seen are due to chance.

### **Rejection**

Rejection is defined as all VADs and ECMOs used for graft failure more than 30 days after heart transplantation.

### **Short-term (ST) devices**

Short-term devices are intended to support for a short period of time (days or weeks). Patients cannot leave hospital with the device.

### **Survival on support**

The percentage of patients who are still alive and on VAD support. Unlike patient survival from implant, survival on support is censored at time of device explantation or transplantation. This is usually specified for a given time period after implantation. For example, a three-year survival on support rate is the estimate of patients who are still alive on support three years after their first short-term or long-term VAD implantation.

### **TAH**

Total Artificial Heart.

## **UK Transplant Registry**

A national database held by NHS Blood and Transplant collecting data on all organ transplant procedures. Information is accrued prospectively at recipient registration on the national transplant list, at organ donation, at time of transplantation and at regular intervals thereafter.

## **Unadjusted survival rate**

Unadjusted [patient survival rates](#) do not take account of potential confounders and are based only on the number of patients at a given centre and the number and timing of those that die within the post-implant period of interest. In this case, unlike for risk-adjusted rates, all patients are assumed to be equally likely to die at any given time. However, some centres may have lower unadjusted survival rates than others simply because they happen to have patients that have increased risks of death. All results presented in this report are unadjusted as the risk factors affecting survival post-MCS in the UK have not yet been examined.

## **VAD**

Ventricular Assist Device.

## **VAD Database**

Database used for an ongoing extensive audit to capture in-depth data prior to and at implant of device, explant, transplant and death along with follow-up at various time points post-implant and post-explant. The database captures data on long-term and short-term mechanical circulatory support, including [VADs](#), [TAH](#) and [ECMO](#), for the purpose of bridge to transplant, bridge to decision (in this report treated the same as bridge to transplant), [primary graft dysfunction](#) and “other” (allowing capture of devices for [rejection](#)). Devices used post-cardiotomy are not funded via the NHS England bridge to transplant or recovery programme and so are excluded from the VAD Database. Destination Therapy is not explicitly captured on the database but these cases may be captured within “bridge to transplant” or “bridge to decision” where the patient never received a transplant.

Prepared by:

Statistics and Clinical Studies, NHS Blood and Transplant

Rachel Hogg  
Sally Rushton

Cardiothoracic Advisory Group (CTAG) Clinical Audit Group

